HAEMONETICS CORP (HAE): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
HAEMONETICS CORP (HAE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 a101-amendedandrestated201.htm EX-10.1 Document Exhibit 10.1 HAEMONETICS CORPORATION AMENDED AND RESTATED 2019 LONG-TERM INCENTIVE COMPENSATION PLAN Effective as of the Effective Date (as defined below), the Haemonetics Corporation 2019 Long-Term Incentive Compensation
How this was made
The 30-second read
Why it matters
For trading, the main value is monitoring potential changes in leadership and incentive structure that could affect future strategy and retention, but the excerpt does not show any immediate financial catalyst.
Market read
This is primarily a governance and equity-compensation filing, with no explicit earnings, guidance, or transaction terms in the provided text.
What to watch
The provided excerpt is largely plan boilerplate; the most market-relevant details would be in the specific director/officer appointment and vote results sections not included here.
Background
The company submitted an SEC Form 8-K covering director/officer changes and related compensatory arrangements, plus submission of matters to a security-holder vote.
Ticker impact
Haemonetics filed an 8-K for director/officer changes and amendments to its 2019 long-term incentive compensation plan.
Likely limited near-term price impact unless the director/officer changes signal a strategic shift.
The filing describes Item 5.02 and an amended and restated long-term incentive plan exhibit, with no earnings, deal, or regulatory outcome disclosed in the provided text.
Market effects
Minimal, as the disclosure is company-specific governance and equity-compensation plan language.
None indicated.
None indicated.
Counterpoint
Even without explicit financial targets, compensation-plan amendments can precede broader restructuring or retention changes, so traders may watch for follow-on disclosures.
Key entities
- issuerHaemonetics Corporation
Subject of the 8-K, including director/officer changes and an amended and restated long-term incentive compensation plan.
